Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future

Journal of Surgical Oncology

Volumn 100, Issue 4, 2009, Pages 335-344

  Nissan, Aviram ^a,b   Stojadinovic, Alexander ^b,c   Garofalo, Alfredo ^d   Esquivel, Jesus ^b,e   Piso, Pompiliu ^f  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b United States Military Cancer Institute   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e ST AGNES HOSPITAL   (United States)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Carcinomatosis; Clinical trial; Cytoreduction; Hyperthermic chemotherapy; Peritoneal surface malignancies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM;

BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; DUODENUM FISTULA; EVIDENCE BASED MEDICINE; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; INFECTION; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PANCREATITIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TIME PERCEPTION;

CLINICAL TRIALS AS TOPIC; HUMANS; PERITONEAL NEOPLASMS;

EID: 69749097864     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21323     Document Type: Conference Paper

References (100)

1. Esquivel J: Cytoreductive surgery for peritoneal malignancies - Development of standards of care for the community. Surg Oncol Clin N Am 2007;16:653-666, x.
2. Al-Shammaa HA, Li Y, Yonemura Y: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008;14:1159-1166. (Pubitemid 351356322)
3. Eggermont AM, Steller EP, Sugarbaker PH: Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of IL-2 and lymphokine-activated killer cells. Surgery 1987;102:71-78.
4. Averbach AM, Jacquet P, Sugarbaker PH: Surgical technique and colorectal cancer: Impact on local recurrence and survival. Tumori 1995;81:65-71.
5. Sugarbaker PH: Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996;82:79-100.
6. Yonemoura Y, editor: Hyperthermo-chemotherapy for the treatment of peritoneal dissemination. In: Contemporary approaches toward cure of gastric cancer. Kanazawa: Maeda Shoten; 1996. pp 105-116.
7. Yonemura Y, Bandou E, Kawamura T, et al.: Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006;32:602-606. (Pubitemid 44063992)
8. Tsujimoto H, Hagiwara A, Shimotsuma M, et al.: Role of milky spots as selective implantation sites for malignant cells in peritoneal dissemination in mice. J Cancer Res Clin Oncol 1996;122:590-595. (Pubitemid 26325585)
9. Tsujimoto H, Takhashi T, Hagiwara A, et al.: Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: Immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells. Br J Cancer 1995;71:468-472.
10. Shimotsuma M, Shields JW, Simpson-Morgan MW, et al.: Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology 1993;26:90-101. Review. (Pubitemid 23213772)
11. Hagiwara A, Takahashi T, Sawai K, et al.: Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 1993;53:687-692. (Pubitemid 23059456)
12. Carmignani CP, Sugarbaker TA, Bromley CM, et al.: Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465-472.
13. Deraco M, Bartlett D, Kusamura S, et al.: Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008;98:268-272.
14. Deraco M, Baratti D, Zaffaroni N, et al.: Advances in clinical research and management of diffuse peritoneal mesothelioma. Recent Results Cancer Res 2007;169:137-155.
15. Bloss JD, Liao SY, Buller RE, et al.: Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-351.
16. Fromm GL, Gershenson DM, Silva EG: Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95.
17. Parkin DM, Bray F, Feraly JPP: Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
18. Esquivel J, Elias D, Baratti D, et al.: Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008;98:263-267.
19. Yan TD, Black D, Sugarbaker PH, et al.: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007;14:2702-2713. (Pubitemid 47460649)
20. Regine WF, Abrams RA: Adjuvant therapy for pancreatic cancer: Current status, future directions. Semin Oncol 2006;33: S10-S13.
21. Stojadinovic A, Brooks A, Hoos A, et al.: An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003;196:954-964. (Pubitemid 36676558)
22. Van Der Burg ME. Advanced ovarian cancer. Curr Treat Options Oncol. 2001; 2:109-118
23. Helm CW, Bristow RE, Kusamura S, et al.: Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008;98:283-290.
24. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
25. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995;221:29-42.
26. González-Moreno S, Kusamura S, Baratti D, et al.: Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol 2008;98:237-241.
27. Loggie BW, Fleming RA, McQuellon RP, et al.: Cytoreductive surgery with intraperitoneal chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561-568.
28. Stewart JH, Shen P, Levine EA: Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Current status and future directions. Ann Surg Oncol 2005;12:756-777. (Pubitemid 41355928)
29. Speyer JL, Collins JM, Dedrick RL, et al.: Phase I and pharmacological studies of 5-fluorouracil administrated intraperitoneally. Cancer Res 1980;40:567-572.
30. Flessner MF, Dedrick RL, Schultz JS: A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985;248:F413-F424. (Pubitemid 15142312)
31. Dedrick RL: Theoretical and experimental basis of intraperitoneal chemotherapy. Semin Oncol 1985;12:1-6.
32. Dedrick RL: Interspecies scaling of regional drug delivery. J Pharm Sci 1986;75:1047-1052.
33. Kuzuya T, Yamauchi M, Ito A, et al.: Pharmacokinetic characteristics of 5-flourourcil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994;46:685-689. (Pubitemid 2124771)
34. Dedrick RL, Flessner MF: Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480-487.
35. Elias D, Bonnay M, Puizillou JM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267-272. (Pubitemid 34704979)
36. Elias D, Matsuhisa T, Sideris L, et al.: Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: Pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558-1565. (Pubitemid 39409748)
37. Sugarbaker PH, Stuart OA, Carmignani CP: Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006;57:703-708.
38. Sugarbaker PH, Graves T, DeBruijn EA, et al.: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990;50:5790-5794.
39. Katz M, Barone R: The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 2003;12:673-688. (Pubitemid 36920092)
40. Spratt JS, Adcock RA, Muskovin M, et al.: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256-260. (Pubitemid 10140145)
41. Teicher BA, Kowal CD, Kennedy KA, et al.: Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096-1099. (Pubitemid 11136367)
42. El-Kareh AW, Secomb TW: A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117-127.
43. VanderWaal R, Thampy G, Wright WD, et al.: Heat-induced modifications in the association of specific proteins with the nuclear matrix. Radiat Res 1996;145:746-753. (Pubitemid 26159523)
44. Roti Roti JL, Kampinga HH, Malyapa RS, et al.: Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998;3:245-255. (Pubitemid 29051824)
45. Pelz JO, Doerfer J, Hohenberger W, et al.: A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 2005;5:56. (Pubitemid 41461074)
46. van Ruth S, Verwaal VJ, Hart AA, et al.: Heat penetration in locally applied hyperthermia in the abdomen during intrapostoperative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003;23:1501-1518.
47. Kerr DJ, Kaye SB: Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987;19:1-5.
48. Los G, Mutsaers PH, van der Vijgh WJ, et al.: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384. (Pubitemid 19162154)
49. Zoetmulder FA: Cancer cell seeding during abdominal surgery: Experimental studies. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: Principles of management. Boston: Kluwer Academic Press; 1996. pp 155-162.
50. Yan TD, Black D, Savady R, et al.: Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011-4019. (Pubitemid 46630752)
51. Hahn GM, Braun J, Har-Kedar I: Thermochemotherapy: Synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975;72:937-940.
52. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980;40:1165-1168.
53. Chu DZ, Lang NP, Thompson C, et al.: Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989;63:364-367. (Pubitemid 19035034)
54. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-1550.
55. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:58-63. (Pubitemid 30051820)
56. Jacquet P, Vidal-Jove J, Zhu B, et al.: Peritoneal carcinomatosis from gastrointestinal malignancy: Natural history and new prospects for management. Acta Chir Belg 1994;94:191-197.
57. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914. (Pubitemid 30727802)
58. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047. (Pubitemid 30162806)
59. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147. (Pubitemid 30036347)
60. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
61. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
62. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237. (Pubitemid 41095086)
63. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
64. Colucci G, Gebbia V, Paoletti G, et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875. (Pubitemid 46223991)
65. Goldberg RM, Sargent DJ, Morton RF, et al.: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006;24:3347-3353.
66. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al.: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-5232. (Pubitemid 350232254)
67. Willet CG, Tepper JE, Cohen AM, et al.: Failure patterns following curative resection of colonic carcinoma. Surgery 1984;200:685-690. (Pubitemid 15216745)
68. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284-3292. (Pubitemid 41103684)
69. Elias D, Blot F, El Otmany A, et al.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71-76. (Pubitemid 32623042)
70. Cavaliere F, Perri P, Rossi CR, et al.: Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: Experience of the Italian Society of Locoregional Integrated Therapy in Oncology. Tumori 2003;89:21-23.
71. Elias D, Pocard M: Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003;12:543-559. (Pubitemid 36920085)
72. Verwaal V, Ruth S, Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743. (Pubitemid 46606227)
73. Glehen O, Cotte E, Schreiber V, et al.: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747-754. (Pubitemid 38746144)
74. Esquivel J, Sticca R, Sugarbaker P, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-133. (Pubitemid 44954279)
75. Crew KD, Neugut AL: Epidemiology of gastric cancer. World J Gastroenterol 2006. 12:354-362.
76. Roviello F, Marrelli D, de Manzoni G, et al.: Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113-1119. (Pubitemid 37152170)
77. Maehara Y, Emi Y, Baba H, et al.: Recurrences and related characteristics of gastric cancer. Br J Cancer 1996;74:975-979. (Pubitemid 26319336)
78. Bando E, Yonemura Y, Takeshita Y, et al.: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999;178:256-262. (Pubitemid 29475109)
79. Wu CW, Lo SS, Shen KH, et al.: Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;327:153-158.
80. Bentrem D, Wilton A, Mazumdar M, et al.: The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 12:347-353. 2005.
81. Kodera Y, Yamamura Y, Shimizu Y, et al.: Peritoneal washing cytology: Prognostic value of positive findings in patient with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999;72:60-64. (Pubitemid 29504122)
82. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83-97. (Pubitemid 19215266)
83. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064.
84. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
85. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. (Pubitemid 34936653)
86. Cervantes A, Roselló S, Roda D, et al.: The treatment of advanced gastric cancer: Current strategies and future perspectives. Ann Oncol 2008;19:v103-v107.
87. Olivier RI, Lubsen-Brandsma MAC, Verhoef S, et al.: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-26. (Pubitemid 41815044)
88. McGuire W, Hoskins W, Brady M, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IVovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
89. Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3194-3200. (Pubitemid 46606249)
90. Albers DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955. (Pubitemid 26428219)
91. Markman M, Bundy B, Albers DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the gynecologic oncology group, southwesters oncology group, and eastern cooperative oncology group. J Clin Oncol 2001;19:1001-1007. (Pubitemid 32176274)
92. Muggia FM, Braly PS, Brady MF, et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2000;18:106-115.
93. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-104.
94. Bristow R, Tomacruz R, Armstrong D, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259. (Pubitemid 34177431)
95. Walker JL, Armstrong DK, Huang HQ, et al.: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2006;100:27-32. (Pubitemid 41815045)
96. de Bree E, Rosing H, Beijnen JH, et al.: Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003;14:103-110. (Pubitemid 36269748)
97. Rufián S, Muńoz-Casares FC, Briceńo J, et al.: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006;94:316-324. (Pubitemid 44330855)
98. Bristow RE, Eisenhauer EL, Santillan A, et al.: Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480-490. (Pubitemid 46135675)
99. Gori J, Castano R, Toziano M, et al.: Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005;15:233-239. (Pubitemid 40396958)
100. Deraco M, Rossi CR, Pennacchioli E, et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori 2001;87:120-126. (Pubitemid 32660378)